The 2019 Aspen Lung Conference
has the following Specific Aims
- To provide an international forum
for leading basic, translational,
and clinical researchers
to exchange ideas regarding fundamental
concepts regarding the pathogenesis and treatment of pulmonary hypertension (PH).
- To stimulate interactions between the fields of pulmonology, cardiology and oncology with the goal of identifying emerging, shared interests that
may will lead
to more efficient and productive research.
- To advance our
understanding of clinical
and molecular PH phenotypes/endotypes
that predict risk or
response in order
quickly translate preclinical findings to more effective, personalized therapies
- To challenge and thereby
stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the
field of PH
Local/Regional/National/International Physicians/Clinicians (adult and pediatric)/Research Physician-Scientists in Pulmonary Sciences, Critical Care and Sleep Medicine/Primary Care Physicians/General Medicine Physicians/Public Health.
The 62nd Annual Meeting, 2019
The Pulmonary Hypertension (PH) field has increasingly
pulmonary vascular pathology
present in pulmonary hypertension
(PH) has neoplastic-like features, including the identification of key
commonalities and now clinical trials of chemotherapy
agents in patients
PH. The 2019 Thomas L. Petty
Aspen Lung Conference will
explore the common mechanisms found in neoplasia and PH, with the overall goal
translating our understanding
of cellular metabolism, proliferation and
signaling into more effective therapies
for patients with PH. The title of the conference is
“Exploring New Therapeutic Pathways in Pulmonary
and Personalized Medicine”.
The four days of the conference will integrate basic,
translational, and clinical approaches while focusing on
in PH: Cellular Metabolism, Hypoxia Signaling, Aberrant Cellular Proliferation and
We have identified 12 speakers who are outstanding scientists in their fields, who will
present State of the Art lectures on these topics. Each of these presentations will be 35 minutes in duration, followed by 25 minutes for discussion to ensure a lively
interaction which is a hallmark of
conference. Inclusion of trainees and junior faculty is emphasized by having two 15-minute
abstracts following each
the Art speaker, selected from submitted
abstracts. There will be two evening poster
sessions for further presentation opportunities by
and trainees. The final
presentation is by
a Conference Summarizer, who reviews the impact
and common themes of the entire
conference proceedings are subsequently published for widespread dissemination.
conference distinguishes itself from other conferences in
the PH field by serving as a “think
discuss the current state
the field and identify
for basic, translation and
clinical research in PH.
There are seven honorary lecturers:
- Parker B. Francis
- Roger S. Mitchell
- Giles F. Filley
- Thomas A. Neff
- Reuben M. Cherniack
- Thomas L. Petty
- Marvin I. Schwarz
We look forward to your participation in the Thomas L. Petty Aspen Lung Conference, 62nd Annual Meeting and to a combination of outstanding science and great fun. We hope that you and your colleagues are able to join us.
Americans with Disabilities Act Statement: Please indicate if you have any need for auxiliary aids or special assistance services.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Colorado School of Medicine and the Aspen Lung Conference. The University of Colorado School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Colorado School of Medicine designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.